Biological Products, (No Diagnostic Substances)

SIC 2836 covers makers of biological products excluding diagnostics, encompassing vaccines, monoclonal antibodies, therapeutic proteins, plasma derivatives, and emerging cell and gene therapies supplied to hospitals, specialty clinics, government health agencies, global health organizations, and biopharma partners. Companies operate under tight FDA/EMA controls, GMP and biosafety requirements, cold-chain and raw-material constraints, patent expirations, and pricing and reimbursement scrutiny. In 2024-2025 the industry is scaling mRNA platforms beyond COVID, pushing personalized cell therapies and gene-editing candidates through pivotal trials, and adopting AI-driven discovery, digital manufacturing, and greener supply chains while reshoring critical inputs to bolster resilience. Core services include contract development and manufacturing for biologics, immunology, oncology, and rare disease indications, alongside lifecycle management and pharmacovigilance. Growth is tempered by regulatory review times, CMC complexity, and competition from biosimilars, but demand remains supported by expanding immunization programs and specialty therapeutics. For the latest capital moves, trials, and compliance updates, view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last fetched 11/23/2025